These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 20056900

  • 1. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma.
    Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, Wenzel SE, Chon Y, Dunn M, Weng HH, Lin SL.
    Am J Respir Crit Care Med; 2010 Apr 15; 181(8):788-96. PubMed ID: 20056900
    [Abstract] [Full Text] [Related]

  • 2. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma.
    Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J, Lin SL.
    Am J Respir Crit Care Med; 2013 Dec 01; 188(11):1294-302. PubMed ID: 24200404
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.
    Busse WW, Wenzel SE, Meltzer EO, Kerwin EM, Liu MC, Zhang N, Chon Y, Budelsky AL, Lin J, Lin SL.
    J Allergy Clin Immunol; 2013 Feb 01; 131(2):339-45. PubMed ID: 23174659
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb 01; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 5. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
    Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, Baumgartner S.
    N Engl J Med; 2012 Mar 29; 366(13):1181-9. PubMed ID: 22455412
    [Abstract] [Full Text] [Related]

  • 6. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma.
    Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, Pavord ID, Zhang B, Staudinger H, Pirozzi G, Amin N, Akinlade B, Eckert L, Chao J, Graham NMH, Teper A.
    Adv Ther; 2018 May 29; 35(5):737-748. PubMed ID: 29725983
    [Abstract] [Full Text] [Related]

  • 7. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial.
    Busse WW, Israel E, Nelson HS, Baker JW, Charous BL, Young DY, Vexler V, Shames RS, Daclizumab Asthma Study Group.
    Am J Respir Crit Care Med; 2008 Nov 15; 178(10):1002-8. PubMed ID: 18787222
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
    Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS.
    Arthritis Rheum; 2002 Dec 15; 46(12):3143-50. PubMed ID: 12483717
    [Abstract] [Full Text] [Related]

  • 9. A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma.
    Oh CK, Leigh R, McLaurin KK, Kim K, Hultquist M, Molfino NA.
    Respir Res; 2013 Sep 19; 14(1):93. PubMed ID: 24050312
    [Abstract] [Full Text] [Related]

  • 10. Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study.
    Majewski S, Slomka S, Zielinska-Wyderkiewicz E, Ciebiada M, Gorski P.
    Am J Cardiovasc Drugs; 2012 Jun 01; 12(3):179-88. PubMed ID: 22409211
    [Abstract] [Full Text] [Related]

  • 11. [Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].
    Wang HY, Lin XP, Hao CL, Zhang CQ, Sun BQ, Zheng JP, Chen P, Sheng JY, Wu A, Zhong NS.
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct 01; 29(10):679-87. PubMed ID: 17129496
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
    Medley H, Orozco S, Allen A.
    Clin Ther; 2012 Aug 01; 34(8):1683-95. PubMed ID: 22796247
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study.
    Lähdeaho ML, Scheinin M, Vuotikka P, Taavela J, Popp A, Laukkarinen J, Koffert J, Koivurova OP, Pesu M, Kivelä L, Lovró Z, Keisala J, Isola J, Parnes JR, Leon F, Mäki M.
    Lancet Gastroenterol Hepatol; 2019 Dec 01; 4(12):948-959. PubMed ID: 31494096
    [Abstract] [Full Text] [Related]

  • 14. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K.
    Allergy; 2005 Mar 01; 60(3):309-16. PubMed ID: 15679715
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study.
    Cellier C, Bouma G, van Gils T, Khater S, Malamut G, Crespo L, Collin P, Green PHR, Crowe SE, Tsuji W, Butz E, Cerf-Bensussan N, Macintyre E, Parnes JR, Leon F, Hermine O, Mulder CJ, RCD-II Study Group Investigators.
    Lancet Gastroenterol Hepatol; 2019 Dec 01; 4(12):960-970. PubMed ID: 31494097
    [Abstract] [Full Text] [Related]

  • 16. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.
    Kulus M, Hébert J, Garcia E, Fowler Taylor A, Fernandez Vidaurre C, Blogg M.
    Curr Med Res Opin; 2010 Jun 01; 26(6):1285-93. PubMed ID: 20377320
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, Fox H, Surrey K.
    Allergy; 2004 Jul 01; 59(7):709-17. PubMed ID: 15180757
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial.
    De Boever EH, Ashman C, Cahn AP, Locantore NW, Overend P, Pouliquen IJ, Serone AP, Wright TJ, Jenkins MM, Panesar IS, Thiagarajah SS, Wenzel SE.
    J Allergy Clin Immunol; 2014 Apr 01; 133(4):989-96. PubMed ID: 24582316
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.
    Holgate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J.
    Curr Med Res Opin; 2001 Apr 01; 17(4):233-40. PubMed ID: 11922396
    [Abstract] [Full Text] [Related]

  • 20. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial.
    Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V, Verleden G, Demedts IK, Verhamme K, Delporte A, Demeyere B, Claeys G, Boelens J, Padalko E, Verschakelen J, Van Maele G, Deschepper E, Joos GF.
    Thorax; 2013 Apr 01; 68(4):322-9. PubMed ID: 23291349
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.